US Pharma MarketingThe post Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial appeared first on Clinical Trials Arena.
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026. Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026. Otsuka announced the data from the Phase IIIb trial of centanafadine in ADHD. Credit: Morumotto / Shutterstock.com Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR 280mg once daily was investigated in adults with ADHD and comorbid anxiety. Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI).…
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.
Source: Clinical Trials Arena